Evidence map›Paper›PMID 42609490›Full record

ArticleHepatology forum2026

TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Yusuf Yilmaz, Gupse Adali, Ilkay Ergenc, Eda Kaya, Dilara Turan Gokce, Caglayan Keklikkiran, Mujdat Zeybel, Gediz Dogay Us, Bulent Degertekin, Ramazan Idilman and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yusuf YilmazDepartment of Gastroenterology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
Gupse AdaliDepartment of Gastroenterology, University of Health Sciences, Istanbul Umraniye Training and Research Hospital, Istanbul, Türkiye.
Ilkay ErgencThe Roger Williams Institute of Liver Studies, King's College Hospital, London, UK.
Eda KayaDepartment of Medicine, University Hospital Knappschaft Kliniken Bochum, Ruhr University Bochum, Bochum, Germany.
Dilara Turan GokceDepartment of Gastroenterology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Caglayan KeklikkiranDepartment of Gastroenterology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
Mujdat ZeybelDepartment of Gastroenterology and Hepatology, Koc University Faculty of Medicine, Istanbul, Türkiye.
Gediz Dogay UsSchool of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
Bulent DegertekinDivision of Gastroenterology and Hepatology, Acibadem Mehmet Ali Aydinlar University Faculty of Medicine, Istanbul, Türkiye.
Ramazan IdilmanDepartment of Gastroenterology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Turkish Association for the Study of the Liver (TASL) Obesity Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Special Interest Group (SIG)
Ulus Salih AkarcaDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Ege University, Izmir, Türkiye.
Zeki KarasuDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Ege University, Izmir, Türkiye.
Sabahattin KaymakogluDivision of Gastroenterohepatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Nurdan TozunDepartment of Gastroenterology, Acibadem Mehmet Ali Aydinlar University Faculty of Medicine, Istanbul, Türkiye.
Ahmet UygunDepartment of Gastroenterology, Gulhane Faculty of Medicine, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and represents a major and growing public health challenge in Türkiye. This guidance provides an updated, clinically oriented overview of the definition, epidemiology, screening, diagnosis, risk stratification, and management of MASLD, with particular emphasis on evolving nomenclature, non-invasive diagnostic pathways, and current treatment strategies. The document addresses the full clinical spectrum of disease, from steatosis and metabolic dysfunction-associated steatohepatitis (MASH) to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. The guidance also incorporates evidence and practice considerations relevant to the Turkish population, including local epidemiology, resource availability, and implementation challenges in real-world care. Finally, areas of uncertainty and evidence gaps are highlighted to support future research and locally relevant policy development.

Indexed as

CirrhosisfibrosisMASHMASLDmetabolic dysfunctionsteatotic liver disease

Identifiers

PMID42609490
PMCPMC13478548

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.